Immunomodulation of antiretroviral drug-suppressed chronic HIV-1 infection in an oral probiotic double-blind placebo-controlled trial

AIDS Research and Human Retroviruses

Volumn 30, Issue 10, 2014, Pages 988-995

  Yang, Otto O ^a,b   Kelesidis, Theodoros ^b   Cordova, Robert ^a   Khanlou, Homayoon ^c  

^a AIDS HEALTHCARE FOUNDATION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Medical Institute of Immunology and Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; C REACTIVE PROTEIN; D DIMER; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; FATTY ACID BINDING PROTEIN 2; FOSAMPRENAVIR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROBIOTIC AGENT; RALTEGRAVIR; RITONAVIR; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BACILLUS COAGULANS; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; FOLLOW UP; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE STATUS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INDIGESTION; MIDDLE AGED; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; VIRUS REPLICATION; HIV INFECTIONS; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; VIROLOGY;

ADMINISTRATION, ORAL; DOUBLE-BLIND METHOD; HIV INFECTIONS; HIV-1; HUMANS; PLACEBOS; PROBIOTICS;

EID: 84907507106     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0181     Document Type: Article

References (41)

1. Mowat AM and Viney JL: The anatomical basis of intestinal immunity. Immunol Rev 1997;156:145-166.
2. Brenchley JM, Schacker TW, Ruff LE, et al.: CD4 + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200(6):749-759.
3. Barouch DH, Liu J, Li H, et al.: Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012;482(7383):89-93.
4. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12(12):1365-1371.
5. Ibarrondo FJ, Wilson SB, Hultin LE, et al.: Depletion of gut CD4-expressing iNKT cells contributes to systemic immune activation in HIV-1 infection. Mucosal Immunol 2012;61:591-600.
6. Poles MA, Boscardin WJ, Elliott J, et al.: Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr 2006;43(1):65-68.
7. Chu H and Mazmanian SK: Innate immune recognition of the microbiota promotes host-microbial symbiosis. Nat Immunol 2013;14(7):668-675.
8. Roederer M, Keele BF, Schmidt SD, et al.: Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 2014;505(7484):502-508.
9. OBrien KL, Liu J, King SL, et al.: Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009;15(8):873-875.
10. Hutnick NA, Carnathan DG, Dubey SA, et al.: Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4 + T cells. Nat Med 2009;15(8):876-878.
11. Klatt NR, Canary LA, Sun X, et al.: Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest 2013; 123(2):903-907.
12. Jensen GS, Benson KF, Carter SG, and Endres JR: GanedenBC30 cell wall and metabolites: Anti-inflammatory and immune modulating effects in vitro. BMC Immunol 2010; 11:15.
13. Kimmel M, Keller D, Farmer S, and Warrino DE: A controlled clinical trial to evaluate the effect of GanedenBC(30) on immunological markers. Methods Find Exp Clin Pharmacol 2010;32(2):129-132.
14. Baron M: A patented strain of Bacillus coagulans increased immune response to viral challenge. Postgrad Med 2009; 121(2):114-118.
15. Mandel DR, Eichas K, and Holmes J: Bacillus coagulans: A viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med 2010;10:1.
16. Dimenas E, Carlsson G, Glise H, et al.: Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl 1996;221:8-13.
17. Belkaid Y and Hand TW: Role of the microbiota in immunity and inflammation. Cell 2014;157(1):121-141.
18. Maathuis AJ, Keller D, and Farmer S: Survival and metabolic activity of the GanedenBC30 strain of Bacillus coagulans in a dynamic in vitro model of the stomach and small intestine. Benef Microbes 2010;1(1):31-36.
19. Endres JR, Clewell A, Jade KA, et al.: Safety assessment of a proprietary preparation of a novel probiotic, Bacillus coagulans, as a food ingredient. Food Chem Toxicol 2009; 47(6):1231-1238.
20. Endres JR, Qureshi I, Farber T, et al.: One-year chronic oral toxicity with combined reproduction toxicity study of a novel probiotic, Bacillus coagulans, as a food ingredient. Food Chem Toxicol 2011;49(5):1174-1182.
21. Kalman DS, Schwartz HI, Alvarez P, et al.: A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulansbased product on functional intestinal gas symptoms. BMC Gastroenterol 2009;9:85.
22. Hun L: Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 2009;121(2):119-124.
23. Wolf BW, Wheeler KB, Ataya DG, and Garleb KA: Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Food Chem Toxicol 1998;36(12):1085-1094.
24. Hummelen R, Changalucha J, Butamanya NL, et al.: Effect of 25 weeks probiotic supplementation on immune function of HIV patients. Gut Microbes 2011;2(2):80-85.
25. Hummelen R, Hemsworth J, Changalucha J, et al.: Effect of micronutrient and probiotic fortified yogurt on immunefunction of anti-retroviral therapy naive HIV patients. Nutrients 2011;3(10):897-909.
26. Trois L, Cardoso EM, and Miura E: Use of probiotics in HIV-infected children: A randomized double-blind controlled study. J Trop Pediatr 2008;54(1):19-24.
27. Gautam N, Dayal R, Agarwal D, et al.: (2014). Role of multivitamins, micronutrients and probiotics supplementation in management of HIV infected children. Indian J Pediatr [Epub ahead of Print]; DOI: 10.1007/s12098-014-1407-6.
28. Anukam KC, Osazuwa EO, Osadolor HB, et al.: Yogurt containing probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/AIDS patients. J Clin Gastroenterol 2008;42(3):239-243.
29. Monachese M, Cunningham-Rundles S, Diaz MA, et al.: Probiotics and prebiotics to combat enteric infections and HIV in the developing world: A consensus report. Gut Microbes 2011;2(3):198-207.
30. Hemsworth JC, Hekmat S, and Reid G: Micronutrient supplemented probiotic yogurt for HIV-infected adults taking HAART in London, Canada. Gut Microbes 2012; 3(5):414-419.
31. Moore DM, Hogg RS, Yip B, et al.: CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/lL. HIV Med 2006;7(6):383-388.
32. Sandler NG, Wand H, Roque A, et al.: Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011;203(6):780-790.
33. Longenecker CT, Jiang Y, Orringer CE, et al.: Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014;28(7):969-977.
34. Hunt PW, Brenchley J, Sinclair E, et al.: Relationship between T cell activation and CD4 + T cell count in HIVseropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197(1):126-133.
35. Burdo TH, Lo J, Abbara S, et al.: Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011;204(8):1227-1236.
36. Baker J, Quick H, Hullsiek KH, et al.: Interleukin-6 and d-dimer levels are associated with vascular dysfunction in patients with untreated HIV infection. HIV Med 2010; 11(9):608-609.
37. Kuller LH, Tracy R, Belloso W, et al.: Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5(10):e203.
38. Haissman JM, Vestergaard LS, Sembuche S, et al.: Plasma cytokine levels in Tanzanian HIV-1-infected adults and the effect of antiretroviral treatment. J Acquir Immune Defic Syndr 2009;52(4):493-497.
39. Chollet-Martin S, Simon F, Matheron S, et al.: Comparison of plasma cytokine levels in African patients with HIV-1 and HIV-2 infection. AIDS 1994;8(7):879-884.
40. Borges AH, OConnor JL, Phillips AN, et al.: Factors associated with D-dimer levels in HIV-infected individuals. PLoS One 2014;9(3):e90978.
41. Funderburg NT, Mayne E, Sieg SF, et al.: Increased tissue factor expression on circulating monocytes in chronic HIV infection: Relationship to in vivo coagulation and immune activation. Blood 2010;115(2):161-167.